Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3)

Conditions:   Breast Cancer;   Renal Cell Carcinoma Interventions:   Drug: IPI-549;   Drug: Atezolizumab;   Drug: nab-paclitaxel;   Drug: Bevacizumab Sponsors:   Infinity Pharmaceuticals, Inc.;   Roche Pharma AG Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials